Columbia Asset Management buys $3,375,145 stake in Amgen (AMGN)

Amgen (AMGN) : Columbia Asset Management scooped up 2,305 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 19,574 shares of Amgen which is valued at $3,375,145.Amgen makes up approximately 1.16% of Columbia Asset Management’s portfolio.

Other Hedge Funds, Including , Bailard boosted its stake in AMGN in the latest quarter, The investment management firm added 465 additional shares and now holds a total of 7,309 shares of Amgen which is valued at $1,260,291. Amgen makes up approx 0.15% of Bailard’s portfolio.Great West Life Assurance Co Can boosted its stake in AMGN in the latest quarter, The investment management firm added 130,975 additional shares and now holds a total of 614,592 shares of Amgen which is valued at $106,588,691. Amgen makes up approx 0.31% of Great West Life Assurance Co Can’s portfolio.Conning reduced its stake in AMGN by selling 9,584 shares or 6.01% in the most recent quarter. The Hedge Fund company now holds 149,984 shares of AMGN which is valued at $25,599,269. Amgen makes up approx 1.06% of Conning’s portfolio.Manchester Capital Management reduced its stake in AMGN by selling 100 shares or 1.6% in the most recent quarter. The Hedge Fund company now holds 6,164 shares of AMGN which is valued at $1,021,190. Amgen makes up approx 0.14% of Manchester Capital Management’s portfolio.First Quadrant L Pca reduced its stake in AMGN by selling 391 shares or 0.11% in the most recent quarter. The Hedge Fund company now holds 347,398 shares of AMGN which is valued at $56,712,724. Amgen makes up approx 1.21% of First Quadrant L Pca’s portfolio.

Amgen opened for trading at $171.48 and hit $174.72 on the upside on Monday, eventually ending the session at $174.58, with a gain of 0.90% or 1.56 points. The heightened volatility saw the trading volume jump to 27,84,334 shares. Company has a market cap of $130,649 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.